Axinn Defeats TRO, Enabling Immediate Launch of Generic Versions of AstraZeneca’s Blockbuster Crestor
July 20, 2016
A team of attorneys from Axinn intervened on behalf of Par Pharmaceutical, Inc. and Apotex Corp. in the U.S. District Court for the District of Columbia to oppose AstraZeneca’s motion for a temporary restraining order. Attorneys from several firms intervened on behalf of five other generic pharmaceutical companies as well. AstraZeneca sought the order to block the FDA from approving generic versions of its top-selling cholesterol drug, Crestor (the fifth largest blockbuster drug on the market). AstraZeneca argued that the FDA cannot approve any generic versions of Crestor because it has so-called orphan drug exclusivity for a rare pediatric use of the drug that would prevent generic competition before 2023.
On July 19, U.S. District Judge Randolph Moss held a TRO hearing at which the Axinn team argued on behalf of all of the Intervenor-Defendants. Judge Moss denied AstraZeneca’s motion for a TRO, allowing generic versions of the drug to enter the market.
Last year, Axinn attorneys also defeated a TRO enabling the immediate launch of generic versions of Otsuka's blockbuster Abilify.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
New Incentives, New Rewards: What You Need to Know About the Antitrust Division’s First-Ever Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
How I Made Partner: 'Show Up and Build Rapport With Colleagues and Clients,' Says Michael O'Mara of Axinn Veltrop & Harkrider
Media Mentions
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property
Chambers Merger Control 2025 Guide
Byline Articles
Antitrust